Clinical evaluation of mineral trioxide aggregate and biodentine as direct pulp capping agents in carious teeth.
Clinical evaluation of mineral trioxide aggregate and biodentine as direct pulp capping agents in carious teeth.
复制标题
DOI：
10.4103/0972-0707.212243
复制
发表时间：
2017-03-01
期刊：
影响因子：
--
通讯作者：
Dinesh, K
中科院分区：
文献类型：
--
作者：
Hegde, Swaroop;Sowmya, B;Dinesh, K
背景：根管治疗一直是牙髓龋暴露的常规治疗选择。在微创牙科的背景下，如果牙髓状态良好，可以考虑使用可靠的生物材料进行直接髓盖（DPC）手术。矿物三氧化物骨料（Mineral trioxide aggregate， MTA）是一种具有生物活性的胶合剂，具有良好的封闭能力和生物相容性，作为DPC剂可以再生相对受损的牙髓，形成牙本质桥。生物牙汀是一种相对较新的生物材料，声称具有与MTA相似的特性，目前正在探索用于重要的牙髓治疗程序。目的：评价MTA联合生物牙本质碱对龋病牙髓-牙本质复合体的临床疗效。对象和方法：选择24颗无不可逆性牙髓炎体征和症状的龋暴露恒磨牙，并将其分为两组，I组- MTA组和II组-生物牙妥定组。患者在3周、3个月和6个月时被召回进行临床和影像学评估。采用Fisher精确检验和卡方检验进行统计分析。结果：在6个月的时间里，根据主观症状、牙髓敏感性测试和x线片表现，MTA和生物牙牙定的成功率分别为91.7%和83.3%。结论：当牙髓炎诊断不多于可逆性牙髓炎时，MTA和生物牙妥定可作为DPC药物。
BACKGROUND: Root canal treatment has been a routine treatment option for carious exposure of the dental pulp. In the context of minimally invasive dentistry, direct pulp capping (DPC) procedure with a reliable biomaterial may be considered as an alternative provided the pulp status is favorable. Mineral trioxide aggregate (MTA), a bioactive cement with excellent sealing ability and biocompatibility is capable of regenerating relatively damaged pulp and formation of dentin bridge when used as DPC agent. Biodentine is comparatively a new biomaterial claimed to possess properties similar to MTA and is currently explored for vital pulp therapy procedures.AIM: The aim of the present study was to evaluate the clinical response of pulp-dentin complex after DPC with MTA and biodentine in carious teeth.SUBJECTS AND METHODS: Twenty-four permanent molars with carious exposure having no signs and symptoms of irreversible pulpitis were selected and assigned to one of the two groups, Group I - MTA and Group II - biodentine. Patients were recalled at 3 weeks, 3 months, and 6 months for clinical and radiographic evaluation. Fisher's exact test was used along with Chi-square test for statistical analysis.RESULTS: Over a period of 6 months, MTA and biodentine showed 91.7% and 83.3% success rate, respectively, based on the subjective symptoms, pulp sensibility tests, and radiographic appearance.CONCLUSION: MTA and biodentine may be used as DPC agents when the pulpal diagnosis is not more than reversible pulpitis.